These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 9220694)

  • 21. Comparison of efficacy and side effects of combination therapy of angiotensin-converting enzyme inhibitor (benazepril) with calcium antagonist (either nifedipine or amlodipine) versus high-dose calcium antagonist monotherapy for systemic hypertension.
    Messerli FH; Oparil S; Feng Z
    Am J Cardiol; 2000 Dec; 86(11):1182-7. PubMed ID: 11090788
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of patients with essential hypertension: amlodipine 5 mg/benazepril 20 mg compared with amlodipine 5 mg, benazepril 20 mg, and placebo.
    Kuschnir E; Acuña E; Sevilla D; Vasquez J; Bendersky M; Resk J; Glazer R
    Clin Ther; 1996; 18(6):1213-24. PubMed ID: 9001838
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of fixed-dose combination therapy in the treatment of patients with hypertension: focus on amlodipine/valsartan.
    da Silva PM
    Clin Drug Investig; 2010; 30(9):625-41. PubMed ID: 20626210
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension.
    Jamerson KA; Nwose O; Jean-Louis L; Schofield L; Purkayastha D; Baron M
    Am J Hypertens; 2004 Jun; 17(6):495-501. PubMed ID: 15177521
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of health costs associated with treatment of hypertension with a calcium channel blocker and angiotensin-converting enzyme inhibitor in the United States and Japan.
    Sakamaki Y; Sasamura H; Ikeda S; Ikegami N; Saruta T
    Hypertens Res; 2006 May; 29(5):333-8. PubMed ID: 16832153
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antiproteinuric effects of combined antihypertensive therapies in patients with overt type 2 diabetic nephropathy.
    Kuriyama S; Tomonari H; Tokudome G; Horiguchi M; Hayashi H; Kobayashi H; Ishikawa M; Hosoya T
    Hypertens Res; 2002 Nov; 25(6):849-55. PubMed ID: 12484508
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).
    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial
    JAMA; 2002 Dec; 288(23):2981-97. PubMed ID: 12479763
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of a step-therapy program for angiotensin receptor blockers on antihypertensive medication utilization patterns and cost of drug therapy.
    Yokoyama K; Yang W; Preblick R; Frech-Tamas F
    J Manag Care Pharm; 2007 Apr; 13(3):235-44. PubMed ID: 17407390
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of 3, 2-Drug Combinations of Antihypertensive Therapies on Blood Pressure Variability in Black African Patients: Secondary Analyses of the CREOLE Trial.
    Ojji DB; Cornelius V; Partington G; Francis V; Pandie S; Smythe W; Hickman N; Barasa F; Damasceno A; Dzudie A; Jones E; Ingabire PM; Mondo C; Ogah O; Ogola E; Sani MU; Shedul GL; Shedul G; Rayner B; Sliwa K; Poulter N;
    Hypertension; 2022 Nov; 79(11):2593-2600. PubMed ID: 36052684
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Amlodipine/benazepril: fixed dose combination therapy for hypertension.
    Faulkner MA; Hilleman DE
    Expert Opin Pharmacother; 2001 Jan; 2(1):165-78. PubMed ID: 11336577
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial.
    Bakris GL; Sarafidis PA; Weir MR; Dahlöf B; Pitt B; Jamerson K; Velazquez EJ; Staikos-Byrne L; Kelly RY; Shi V; Chiang YT; Weber MA;
    Lancet; 2010 Apr; 375(9721):1173-81. PubMed ID: 20170948
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of benazepril amlodipine combination on fibrinolysis in hypertensive diabetic patients.
    Fogari R; Preti P; Lazzari P; Corradi L; Zoppi A; Fogari E; Mugellini A
    Eur J Clin Pharmacol; 2003 Aug; 59(4):271-5. PubMed ID: 12830340
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of amlodipine and benazepril monotherapy to amlodipine plus benazepril in patients with systemic hypertension: a randomized, double-blind, placebo-controlled, parallel-group study. The Benazepril/Amlodipine Study Group.
    Frishman WH; RAM CV; McMahon FG; Chrysant SG; Graff A; Kupiec JW; Hsu H
    J Clin Pharmacol; 1995 Nov; 35(11):1060-6. PubMed ID: 8626878
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination therapy with amlodipine/benazapril (CCB/ACEI) superior to hydrochlorothiazide/benazapril in high-risk hypertensive patients.
    Cardiovasc J Afr; 2008; 19(3):163. PubMed ID: 18568181
    [No Abstract]   [Full Text] [Related]  

  • 35. Combinations of inhibitors of the renin-angiotensin system with calcium channel blockers for the treatment of hypertension: focus on perindopril/amlodipine.
    Mourad JJ; Le Jeune S; Pirollo A; Mourad C; Gaudouen Y; Lopez-Sublet M
    Curr Med Res Opin; 2010 Sep; 26(9):2263-76. PubMed ID: 20690889
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fixed-dose combinations of renin-angiotensin blocking agents with calcium channel blockers or hydrochlorothiazide in the treatment of hypertension.
    Bramlage P
    Expert Opin Pharmacother; 2009 Aug; 10(11):1755-67. PubMed ID: 19538001
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of single-pill and separate-pill administration of antihypertensive triple combination therapy: a population-based microsimulation study.
    Morabito G; Gregorio C; Ieva F; Barbati G; Mancia G; Corrao G; Rea F
    BMC Public Health; 2024 Jul; 24(1):1808. PubMed ID: 38971775
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An eight-week, multicenter, randomized, double-blind study to evaluate the efficacy and tolerability of fixed-dose amlodipine/benazepril combination in comparison with amlodipine as first-line therapy in chinese patients with mild to moderate hypertension.
    Ueng KC; Lin LC; Voon WC; Lin MC; Liu YB; Su HM; Chang PY; Lin TH; Chen WL; Wu CC; Lai WT; Lin CS
    Blood Press Suppl; 2008 Jun; 1():24-31. PubMed ID: 18705532
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prior Medications and the Cardiovascular Benefits From Combination Angiotensin-Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High-Risk Hypertensive Patients.
    Brook RD; Kaciroti N; Bakris G; Dahlöf B; Pitt B; Velazquez E; Weber M; Zappe DH; Hau T; Jamerson KA
    J Am Heart Assoc; 2018 Jan; 7(1):. PubMed ID: 29301757
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An economic evaluation of the JNC hypertension guidelines using data from a randomized controlled trial. Joint National Committee.
    Ramsey SD; Neil N; Sullivan SD; Perfetto E
    J Am Board Fam Pract; 1999; 12(2):105-14. PubMed ID: 10220232
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.